An Expanded Access Open Label Study of CB7630 (Abiraterone Acetate) in Patients With Advanced Prostate Cancer Who Have Completed CB7630 Clinical Study COU-AA-001 [EXTENSION OF 700020097]
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Abiraterone acetate (Primary)
- Indications Prostate cancer
- Focus Expanded access; Therapeutic Use
- Sponsors Janssen Research & Development
- 14 Feb 2013 New trial record